Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience

Krzysztof Mrózek, Andrew J. Carroll, Kati Maharry, Kathleen W. Rao, Shivanand R. Patil, Mark J. Pettenati, Michael S. Watson, Diane C. Arthur, Ramana Tantravahi, Nyla A. Heerema, Prasad R K Koduru, Annemarie W. Block, Mazin B. Qumsiyeh, Colin G. Edwards, Lisa J. Sterling, Kelsi B. Holland, Clara D. Bloomfield

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The Cancer and Leukemia Group B has performed central review of karyotypes submitted by institutional cytogenetics laboratories from patients with acute myeloid (AML) and acute lymphoblastic (ALL) leukemia since 1986. We assessed the role of central karyotype review in maintaining accurate, high quality cytogenetic data for clinical and translational studies using two criteria: the proportion of karyotypes rejected (i.e. inadequate), and, among accepted (i.e. adequate) cases, the proportion of karyotypes whose interpretation was changed on central karyotype review. We compared the first four years during which central karyotype review was performed with a recent 4-year period and found that the proportion of rejected samples decreased significantly for both AML and ALL. However, during the latter period, central karyotype reviews still found 8% of AML and 16% of ALL karyotypes inadequate. Among adequate cases, the karyotype was revised in 26% of both AML and ALL samples. Some revisions resulted in changing the patients' assignment to particular World Health Organization diagnostic categories and/or moving patients from one prognostic group to another. Overall, when both data on rejection rates and data on karyotype revisions made in accepted cases were considered together, 32% of AML and 38% of ALL samples submitted were either rejected or revised on central karyotype review during the recent 4-year period. These data underscore the necessity of continued central karyotype review in multi-institutional cooperative group studies.

Original languageEnglish (US)
Pages (from-to)239-244
Number of pages6
JournalInternational Journal of Oncology
Volume33
Issue number2
DOIs
StatePublished - Aug 2008

Fingerprint

Karyotype
Cytogenetics
Leukemia
Neoplasms
Clinical Studies
Moving and Lifting Patients
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Keywords

  • Acute leukemia
  • Chromosome aberrations
  • Correlative studies
  • Human
  • Karyotyping

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia : The Cancer and Leukemia Group B experience. / Mrózek, Krzysztof; Carroll, Andrew J.; Maharry, Kati; Rao, Kathleen W.; Patil, Shivanand R.; Pettenati, Mark J.; Watson, Michael S.; Arthur, Diane C.; Tantravahi, Ramana; Heerema, Nyla A.; Koduru, Prasad R K; Block, Annemarie W.; Qumsiyeh, Mazin B.; Edwards, Colin G.; Sterling, Lisa J.; Holland, Kelsi B.; Bloomfield, Clara D.

In: International Journal of Oncology, Vol. 33, No. 2, 08.2008, p. 239-244.

Research output: Contribution to journalArticle

Mrózek, K, Carroll, AJ, Maharry, K, Rao, KW, Patil, SR, Pettenati, MJ, Watson, MS, Arthur, DC, Tantravahi, R, Heerema, NA, Koduru, PRK, Block, AW, Qumsiyeh, MB, Edwards, CG, Sterling, LJ, Holland, KB & Bloomfield, CD 2008, 'Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience', International Journal of Oncology, vol. 33, no. 2, pp. 239-244. https://doi.org/10.3892/ijo_00000002
Mrózek, Krzysztof ; Carroll, Andrew J. ; Maharry, Kati ; Rao, Kathleen W. ; Patil, Shivanand R. ; Pettenati, Mark J. ; Watson, Michael S. ; Arthur, Diane C. ; Tantravahi, Ramana ; Heerema, Nyla A. ; Koduru, Prasad R K ; Block, Annemarie W. ; Qumsiyeh, Mazin B. ; Edwards, Colin G. ; Sterling, Lisa J. ; Holland, Kelsi B. ; Bloomfield, Clara D. / Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia : The Cancer and Leukemia Group B experience. In: International Journal of Oncology. 2008 ; Vol. 33, No. 2. pp. 239-244.
@article{f25cce83cc3741c68300bc2821f4664c,
title = "Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: The Cancer and Leukemia Group B experience",
abstract = "The Cancer and Leukemia Group B has performed central review of karyotypes submitted by institutional cytogenetics laboratories from patients with acute myeloid (AML) and acute lymphoblastic (ALL) leukemia since 1986. We assessed the role of central karyotype review in maintaining accurate, high quality cytogenetic data for clinical and translational studies using two criteria: the proportion of karyotypes rejected (i.e. inadequate), and, among accepted (i.e. adequate) cases, the proportion of karyotypes whose interpretation was changed on central karyotype review. We compared the first four years during which central karyotype review was performed with a recent 4-year period and found that the proportion of rejected samples decreased significantly for both AML and ALL. However, during the latter period, central karyotype reviews still found 8{\%} of AML and 16{\%} of ALL karyotypes inadequate. Among adequate cases, the karyotype was revised in 26{\%} of both AML and ALL samples. Some revisions resulted in changing the patients' assignment to particular World Health Organization diagnostic categories and/or moving patients from one prognostic group to another. Overall, when both data on rejection rates and data on karyotype revisions made in accepted cases were considered together, 32{\%} of AML and 38{\%} of ALL samples submitted were either rejected or revised on central karyotype review during the recent 4-year period. These data underscore the necessity of continued central karyotype review in multi-institutional cooperative group studies.",
keywords = "Acute leukemia, Chromosome aberrations, Correlative studies, Human, Karyotyping",
author = "Krzysztof Mr{\'o}zek and Carroll, {Andrew J.} and Kati Maharry and Rao, {Kathleen W.} and Patil, {Shivanand R.} and Pettenati, {Mark J.} and Watson, {Michael S.} and Arthur, {Diane C.} and Ramana Tantravahi and Heerema, {Nyla A.} and Koduru, {Prasad R K} and Block, {Annemarie W.} and Qumsiyeh, {Mazin B.} and Edwards, {Colin G.} and Sterling, {Lisa J.} and Holland, {Kelsi B.} and Bloomfield, {Clara D.}",
year = "2008",
month = "8",
doi = "10.3892/ijo_00000002",
language = "English (US)",
volume = "33",
pages = "239--244",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia

T2 - The Cancer and Leukemia Group B experience

AU - Mrózek, Krzysztof

AU - Carroll, Andrew J.

AU - Maharry, Kati

AU - Rao, Kathleen W.

AU - Patil, Shivanand R.

AU - Pettenati, Mark J.

AU - Watson, Michael S.

AU - Arthur, Diane C.

AU - Tantravahi, Ramana

AU - Heerema, Nyla A.

AU - Koduru, Prasad R K

AU - Block, Annemarie W.

AU - Qumsiyeh, Mazin B.

AU - Edwards, Colin G.

AU - Sterling, Lisa J.

AU - Holland, Kelsi B.

AU - Bloomfield, Clara D.

PY - 2008/8

Y1 - 2008/8

N2 - The Cancer and Leukemia Group B has performed central review of karyotypes submitted by institutional cytogenetics laboratories from patients with acute myeloid (AML) and acute lymphoblastic (ALL) leukemia since 1986. We assessed the role of central karyotype review in maintaining accurate, high quality cytogenetic data for clinical and translational studies using two criteria: the proportion of karyotypes rejected (i.e. inadequate), and, among accepted (i.e. adequate) cases, the proportion of karyotypes whose interpretation was changed on central karyotype review. We compared the first four years during which central karyotype review was performed with a recent 4-year period and found that the proportion of rejected samples decreased significantly for both AML and ALL. However, during the latter period, central karyotype reviews still found 8% of AML and 16% of ALL karyotypes inadequate. Among adequate cases, the karyotype was revised in 26% of both AML and ALL samples. Some revisions resulted in changing the patients' assignment to particular World Health Organization diagnostic categories and/or moving patients from one prognostic group to another. Overall, when both data on rejection rates and data on karyotype revisions made in accepted cases were considered together, 32% of AML and 38% of ALL samples submitted were either rejected or revised on central karyotype review during the recent 4-year period. These data underscore the necessity of continued central karyotype review in multi-institutional cooperative group studies.

AB - The Cancer and Leukemia Group B has performed central review of karyotypes submitted by institutional cytogenetics laboratories from patients with acute myeloid (AML) and acute lymphoblastic (ALL) leukemia since 1986. We assessed the role of central karyotype review in maintaining accurate, high quality cytogenetic data for clinical and translational studies using two criteria: the proportion of karyotypes rejected (i.e. inadequate), and, among accepted (i.e. adequate) cases, the proportion of karyotypes whose interpretation was changed on central karyotype review. We compared the first four years during which central karyotype review was performed with a recent 4-year period and found that the proportion of rejected samples decreased significantly for both AML and ALL. However, during the latter period, central karyotype reviews still found 8% of AML and 16% of ALL karyotypes inadequate. Among adequate cases, the karyotype was revised in 26% of both AML and ALL samples. Some revisions resulted in changing the patients' assignment to particular World Health Organization diagnostic categories and/or moving patients from one prognostic group to another. Overall, when both data on rejection rates and data on karyotype revisions made in accepted cases were considered together, 32% of AML and 38% of ALL samples submitted were either rejected or revised on central karyotype review during the recent 4-year period. These data underscore the necessity of continued central karyotype review in multi-institutional cooperative group studies.

KW - Acute leukemia

KW - Chromosome aberrations

KW - Correlative studies

KW - Human

KW - Karyotyping

UR - http://www.scopus.com/inward/record.url?scp=48749119622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48749119622&partnerID=8YFLogxK

U2 - 10.3892/ijo_00000002

DO - 10.3892/ijo_00000002

M3 - Article

C2 - 18636143

AN - SCOPUS:48749119622

VL - 33

SP - 239

EP - 244

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 2

ER -